Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: High Blood Pressure
Interventions: Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 59 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, SOC; Biological · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Food Insecurity, Hypertension, Nutrition, Disease Management
Interventions: Food Resources & Kitchen Skills (FoRKS), Enhanced Usual Care (EUC); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Portal Hypertension, Cirrhosis
Interventions: HVPG, Indocyanine Green Retention test, Liver stiffness measurement, Spleen stiffness measurement; Procedure · Drug · Device
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Liver Cirrhosis
Interventions: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pregnancy Related, Hypertension, Obesity, Racism
Interventions: COH+; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Surface Disease
Interventions: Xiidra (Lifitegrast ophthalmic solution) 5%; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Hypertension, High Blood Pressure
Interventions: LINKED-BP Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bowie, Maryland + 11 more

Conditions: Pulmonary Hypertension of Newborn
Interventions: INOmax; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 27 Weeks to 40 Weeks
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Hypertension
Interventions: Diet and Lifestyle; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,761 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: CHF, Renal Disease, Hypertension
Interventions: Not listed
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open-angle Glaucoma or Ocular Hypertension
Interventions: DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more

Conditions: Hypertension
Interventions: Glucose; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: High Blood Pressure
Interventions: Salt pills, Placebo pills; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Pulmonary Arterial Hypertension
Interventions: Carvedilol; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypertension
Interventions: L-citrulline; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Adrenocortical Carcinoma
Interventions: Relacorilant, Pembrolizumab; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Glaucoma, Open-Angle, Glaucoma
Interventions: iStent Inject Implantation; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Phoenix, Arizona • Torrance, California • Dallas, Texas

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Practice Facilitation; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New York, New York

Conditions: Hypertension, Pulmonary
Interventions: Carbon Monoxide; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Para-aminohippuric Acid, Angiotensin II, Norepinephrine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Treating Nocturnal Hypertension and Nocturia in African American Men

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Topical Insulin for Glaucoma (TING2)

Delivering Food Resources & Kitchen Skills (FoRKS) to Adults With Food Insecurity and Hypertension

Surrogate Markers of Portal Pressure

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Topical Insulin for Glaucoma

The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Discovering Healthcare Innovations to Address Disparities in Stroke (DIADS)

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Validation of a Sensor for Non-Invasive Measurements

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

Salt and Gut Study

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

iStent Inject New Enrollment Post-Approval Study

Team-based Care to Improve Hypertension

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

Genetic Mechanisms in Human Hypertension